Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018: Melanoma highlights

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 502
Rating:

Dr Teresa Amaral, Will Davies

Dr Teresa Amaral speaks with Will Davies at ESMO 2018 in Munich about essential news from melanoma trials.

She highlights the data underlying surgical standards and new classifications in melanoma following presentations at ASCO 2018, and emerging data from the neoadjuvant setting including OPACIN-neo and combination immunotherapies.

She also highlights the triplet therapy of dabrafenib and trametinib with pembrolizumab in the Keynote022 trial, as presented by Prof Paolo Ascierto.

Related videos

follow us

War on Cancer 2018


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation